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ABSTRACT
Objectives: The International Cancer Benchmarking
Partnership (ICBP) is a collaboration between 6
countries and 12 jurisdictions with similar primary
care-led health services. This study investigates
primary care physician (PCP) behaviour and systems
that may contribute to the timeliness of investigating
for cancer and subsequently, international survival
differences.
Design: A validated survey administered to PCPs via
the internet set out in two parts: direct questions on
primary care structure and practice relating to cancer
diagnosis, and clinical vignettes, assessing
management of scenarios relating to the diagnosis of
lung, colorectal or ovarian cancer.
Participants: 2795 PCPs in 11 jurisdictions: New
South Wales and Victoria (Australia), British Columbia,
Manitoba, Ontario (Canada), England, Northern Ireland,
Wales (UK), Denmark, Norway and Sweden.
Primary and secondary outcome measures:
Analysis compared the cumulative proportion of PCPs
in each jurisdiction opting to investigate or refer at
each phase for each vignette with 1-year survival, and
conditional 5-year survival rates for the relevant cancer
and jurisdiction. Logistic regression was used to
explore whether PCP characteristics or system
differences in each jurisdiction affected the readiness
to investigate.
Results: 4 of 5 vignettes showed a statistically
significant correlation (p<0.05 or better) between
readiness to investigate or refer to secondary care at
the first phase of each vignette and cancer survival
rates for that jurisdiction. No consistent associations
were found between readiness to investigate and
selected PCP demographics, practice or health system
variables.
Conclusions: We demonstrate a correlation between
the readiness of PCPs to investigate symptoms
indicative of cancer and cancer survival rates, one of
the first possible explanations for the variation in
cancer survival between ICBP countries. No specific
health system features consistently explained these
findings. Some jurisdictions may consider lowering
thresholds for PCPs to investigate for cancer—either
directly, or by specialist referral, to improve outcomes.
INTRODUCTION
Signiﬁcant differences in cancer survival
have been demonstrated between countries
with similar health systems.1 Poor outcomes
may arise from late presentation, diagnostic
delays and treatment differences, or combi-
nations of these.1–6 There is some evidence
that delay between presentation and diagno-
sis (the diagnostic interval)7 is associated
with poorer outcomes,8–11 but the factors
involved are complex and the strength of the
relationship is unclear. Detailed knowledge
about how the diagnostic interval is managed
in health systems may explain these differ-
ences in survival.
Strengths and limitations of this study
▪ A novel, large and logistically complicated study
using a validated survey.
▪ Data were analysed from 2795 primary care phy-
sicians (PCPs) across 11 jurisdictions.
▪ Response rates were suboptimal (ranging from
5.5% in England and British Columbia to 45.6%
in Manitoba) and respondents were not totally
representative of the PCPs in all jurisdictions.
▪ It is difficult to assess the effect of these weak-
nesses on the interpretation of results but sensi-
tivity analyses and the literature suggest it would
not be large.
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The International Cancer Benchmarking Partnership
(ICBP) is a collaboration across 6 countries (Australia,
Canada, Denmark, Norway, Sweden and the UK) and 12
jurisdictions of comparable wealth and universal access
to healthcare, established to examine international dif-
ferences in cancer outcomes and identify possible
causes. Cancer survival is higher in Australia, Canada
and Sweden, intermediate in Norway, and lower in
Denmark and the UK.1 Differences between the coun-
tries in the proportion of patients diagnosed with the
cancer at an early stage, suggest that differences in the
period prior to diagnosis contribute to the international
variation in cancer survival, along with other potential
factors, such as access to treatment and the quality of
treatments.2–6
Public awareness of signs and symptoms, and beliefs
about cancer, appear to be quite similar across jurisdic-
tions and are therefore unlikely to account for much of
the variation seen between countries. However, differ-
ences in perceived barriers to seeing the general practi-
tioner (GP) have been reported.12 Differences in the
way cancer symptoms are recognised and managed in
primary care may contribute to the observed survival dif-
ferences. For example, European intercountry differ-
ences in clinical diagnostic practice have been reported
for gastrointestinal disorders.13 A stronger ‘gatekeeper’
role—whereby primary care physicians (PCPs) manage
entry to specialist care and investigations—is also asso-
ciated with worse cancer survival.14 This ‘gatekeeper
issue’ is exempliﬁed by the ﬁnding that higher rates of
endoscopy referrals within individual UK general prac-
tices are associated with a lower mortality from oesopha-
gogastric cancer.15 There are many system factors that
will inﬂuence a PCPs decision to act, including guide-
lines, access to investigations, and culture of collabor-
ation between primary and secondary care, and these
will all contribute to PCP behaviour.16
The aims of this study were to describe the readiness
of PCPs to consider investigation or referral for symp-
toms possibly indicative of cancer, and to relate this to
international differences in primary care structure and
practice. Our hypothesis was that there is a positive cor-
relation between the proportion of PCPs who would
investigate a speciﬁc symptom set for cancer and survival
rates (for the given cancer) across jurisdictions. We also
investigated whether the readiness of PCPs to investigate
these cases could be explained by differences in primary
care structure or PCP characteristics.
METHODS
We conducted an international vignette survey among a
sample of PCPs in participating jurisdictions.
Survey development
We developed an online survey of PCPs exploring differ-
ences in their behaviours, attitudes, knowledge and skills
relating to cancer diagnosis. Development involved
iterative discussion with international partners at every
stage of development. The overall validation was initially
undertaken in England, with two rounds of validation,
using a cognitive interviewing technique with PCPs fol-
lowing completion of the draft survey. Validation of the
completed survey was tested in all jurisdictions, particu-
larly to ensure that translation had not altered meaning.
There were two questions relating to access to tests and
internal consistency was measured by comparison of the
answers to these questions. The development and valid-
ation has been described in detail elsewhere.17
Structure
The survey was in two parts: ﬁrst, direct questions con-
sisting of demographic details of the respondents and
questions relating to service provision, access to investi-
gations and waiting times following secondary care refer-
rals; and second, vignettes on management choices for a
patient presenting with symptoms suggestive of either
lung (two vignettes), colorectal (two vignettes) or
ovarian cancer (one vignette). Respondents were ran-
domly presented with two vignettes (of different cancer
sites), and were asked to complete the survey relating to
their own practice rather than perceived best practice.
Respondents were aware that the survey was part of a
study linked to cancer.
Each vignette had two or three phases: phase 1 repre-
sented the ﬁrst patient presentation; phases 2 and 3
represented subsequent visits, where the patient’s symp-
toms had developed; each phase had a predeﬁned posi-
tive predictive value (PPV) for the cancer, based on
previous work, to ensure a deﬁned increase in cancer risk
at each phase (table 1).18–20 Respondents were not
informed of the PPV for each set of symptoms and signs
in the survey. However, specifying the PPVs in the analysis
at each phase enabled a comparison of the readiness to
act within vignettes and between vignettes of the same
cancer. The response of primary interest was opting to
identify possible cancer either by referral to secondary
care or by undertaking a deﬁnitive diagnostic investiga-
tion in primary care: requesting either of these ended
that vignette. The deﬁnitive tests were determined by an
expert panel and included chest X-ray or lung CT for
lung vignettes, colonoscopy or abdominal CT for colorec-
tal vignettes and abdominal CT or abdominal or transva-
ginal ultrasound for the ovarian vignette.17
The final survey
The survey was completed in 11 jurisdictions: New South
Wales and Victoria (Australia), British Columbia,
Manitoba, Ontario (Canada), England, Northern Ireland,
Wales (UK), Denmark, Norway and Sweden. All surveys
were completed online.
Each jurisdiction decided on a method of sampling
and approach to potential participants (by post or
email), depending on local conditions and the availabil-
ity of databases with PCP contact details, and participa-
tion incentives. While variation in sampling methods and
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Table 1 Summary of the vignettes
Vignette Cancer Patient details
Management options Phase 1 Phase 2
Correlation between survival
and referral or test at phase 1
(weighted regression
analysis)
Definitive
actions Non-definitive actions PPV
Refer/
test
(%)* PPV
Refer/
test
(%)*
1-year
survival
p Value
Conditional
5-year
survival
p Value
1 Lung Phase 1 68-year-old woman, exsmoker with
persistent cough for 3 weeks but no other
symptoms, taking ramipril for
hypertension. Ear, throat and chest
examinations were normal
Secondary
care referral
Chest X-ray
Chest CT
▸ Antibiotics
▸ Oral steroids
▸ Antitussive medicines
▸ Stop ramipril
▸ Advise visit to
pharmacy to try
remedies there
▸ Tell her that no action
is needed at this
stage
0.9 40–80 3.9 95–100 0.654 0.647
Phase 2 The patient returns after another 3 weeks,
saying cough has persisted and now there
are streaks of blood in the sputum. No
weight loss, but a chest examination
reveals some crepitations at the left base.
Any tests previously undertaken were
normal
0.357
(excluding
Denmark)
0.911
(excluding
Denmark)
Phase 3 The patient returns with ongoing
symptoms and you decide to order a chest
X-ray. The report says there is mild
cardiomegaly but the lung fields are clear
2 Lung Phase 1 62-year-old man with COPD, a heavy
smoker for over 40 years. He presented
with respiratory symptoms
Secondary
care referral
Chest X-ray
Chest CT
▸ Advise increased use
of salbutamol inhaler
▸ Antibiotics
▸ Oral steroids
▸ Antibiotics and add
new inhaler steroid or
salmeterol
▸ Antitussive medicines
▸ Advise visit to
pharmacy to try
remedies there
▸ Tell him that no action
is needed at this
stage
3.6 5–50 >10.0 87–100 <0.001 <0.001
Phase 2 The patient returns in 3 weeks, reported
constant ache in left shoulder. The patient
attributes pain to persistent cough; he is
also producing grey coloured sputum in
larger quantities than usual, but no other
chest symptoms. No weight loss. On
examination he still has a bilateral upper
lobe wheeze and some crepitations at the
left base. Examination of his shoulder is
normal
<0.001
(excluding
Denmark)
<0.001
(excluding
Denmark)
3 Colorectal Phase 1 43-year-old woman with IBS for more than
10 years, but the IBS has got worse
recently. She has abdominal pain every
day, unchanged bowel habit and no other
symptoms. She has no family history of
cancer.
Secondary
care referral
Colonoscopy
Abdominal CT
▸ Prescribe medication
for IBS
▸ Give dietary advice
▸ Offer psychological
therapies (counselling
and CBT)
▸ Tell her that no action
is needed at this
stage
0.7 5–45 1.2 48–89 0.014 0.025
Phase 2 The patient returns. Her recent blood test
has returned a haemoglobin level of
10.5 g/dL.
0.003
(excluding
Denmark)
0.002
(excluding
Denmark)
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Table 1 Continued
Vignette Cancer Patient details
Management options Phase 1 Phase 2
Correlation between survival
and referral or test at phase 1
(weighted regression
analysis)
Definitive
actions Non-definitive actions PPV
Refer/
test
(%)* PPV
Refer/
test
(%)*
1-year
survival
p Value
Conditional
5-year
survival
p Value
4† Colorectal Phase 1 68-year-old man with no relevant medical
history. He has experienced loose stools
twice a day, most days for over 4 weeks.
He has no other symptoms. Examination
included rectal examination which was
normal.
Secondary
care referral
Colonoscopy
Abdominal CT
▸ Offer medication, eg,
loperamide,
antispasmodic,
analgaesia
▸ Advice on diet
▸ Tell him that no action
is needed at this
stage
0.9 20–40 1.9 77–89 0.071 0.093
Phase 2 Any tests selected are negative. The
patient returns 2 weeks later, describing
that the diarrhoea remains much the same
but he now also has intermittent sharp
abdominal pain. Abdominal and PR
examinations are normal.
0.004
(excluding
Denmark)
0.001
(excluding
Denmark)
Phase 3 All tests are negative. A further 2 weeks
later the patient describes two brief
episodes of rectal bleeding (bright red)
2 days apart.
5† Ovarian Phase 1 53-year-old woman whose last period was
6 months ago. She had experienced
abdominal pain for the past 3 weeks. She
has had no other symptoms and the same
sexual partner for 20 years.
Secondary
care referral
Abdominal
ultrasound
Pelvic CT
▸ Prescribe analgesia
▸ Prescribe
antispasmodic
▸ Undertake
investigations now
▸ Tell her that no action
is needed at this
stage
0.3 40–75 0.7 68–90 0.007 0.610
Phase 2 All investigations to date have been
normal. The patient presents 1-month later
with urinary frequency. She says the
abdominal pain is still present but comes
less often. Abdominal examination is
normal. A urine dipstick for blood, protein,
nitrite, white cells and sugar is negative.
0.009
(excluding
Denmark)
0.744
(excluding
Denmark)
Phase 3 The patient returns 6 weeks later saying
pain is worse, she is passing urine every
3 h, day and night and has noticed that
her abdomen seems swollen. After
examination of her abdomen, it does look
distended but cannot feel any other
abnormality.
*Range of respondent who completed the vignette at this stage by referral or undertaking a definitive diagnostic test.
†Stage 3 results not reported as nearly all respondents referred or undertook definitive test by this stage.
Bold typeface indicates significance.
CBT, cognitive behavioural therapy; COPD, chronic obstructive pulmonary disease; IBS, irritable bowel syndrome; PPV, positive predictive value; PR, rectal examination.
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approaches might be expected to introduce sample bias,
and to affect response rates, there are no observable
trends that would suggest that this is true (see online
supplementary table S1).
Participants
Participants were PCPs working predominantly in clin-
ical practice, including locums; retired PCPs and those
in training were not eligible. Considering all jurisdic-
tions, the online surveys were completed between May
2012 and July 2013; the start dates and end dates in
each jurisdiction varied.
The representativeness of each sample was assessed by
comparing gender, age and place of qualiﬁcation between
respondents, and data for all PCPs in each jurisdiction.
All participants gave their consent for their data to be
used by completing the online survey. Approvals to
conduct this study were sought from ethics committees in
each jurisdiction (see online supplementary table S2).
Sample size
Each jurisdiction aimed to recruit at least 200 respondents.
This provided a 95% CI ±7% for equally distributed
responses (eg, 50% responding ‘yes’), and ±6% CI for less
equally distributed responses (eg, 20% responding ‘yes’).
Analysis
Direct questions relating to demographics and primary
care structure factors were analysed using descriptive sta-
tistics. The questions relating to average waiting times
for tests and results were analysed by estimating the
mean time from ordering a test to receiving the results
by using the midpoint of each waiting time category.
Analysis of the vignettes was undertaken in two stages.
Our hypothesis was explored by comparing the cumula-
tive proportion of PCPs opting to investigate or refer at
each phase for each vignette using percentage 1-year
survival rates in each jurisdiction for the relevant cancer.
Linear correlations were estimated between the propor-
tions opting to investigate at each phase and survival rates.
Weighted regression
When comparing between jurisdictions, weighted linear
regression was used to adjust for different sample sizes
in each jurisdiction, based on the total number of
respondents for each vignette. A regression model was
ﬁtted for each phase and each vignette using 1-year sur-
vival as the outcome, with the number of PCPs acting at
each phase as a single explanatory variable. The weights
were the inverse of the variance of the proportion at a
given phase for each jurisdiction. No weighted regres-
sion models were possible for jurisdictions where all
PCPs had opted to investigate at a given phase.
Logistic regression: multilevel model
Weighted regression did not allow us to explore if individ-
ual PCP characteristics and access to tests (within each
jurisdiction) were associated with opting to investigate.
Therefore, in the second stage of the analysis, we ﬁtted
separate multilevel logistic regression models using
opting to investigate as the outcome and estimated the
association with (A) PCP characteristics, (B) access to
tests, (C) jurisdiction level survival (1-year and condi-
tional 5-year survival) as reported by Coleman et al,1 and
(D) a full model including PCP characteristics and access
to tests. This last model only included those variables sig-
niﬁcantly associated in models (A) and (B) to reduce the
chances of identifying spurious associations.
We identiﬁed variables that might inﬂuence opting to
investigate in models (A) and (B), as well as the
expected direction of effect (see online supplementary
table S3). As with the weighted regression, analyses were
performed by vignette as explanatory variables were dif-
ferent for each cancer. These variables are not inde-
pendent and therefore some basic model selection
(based on statistical signiﬁcant associations p value
<0.05) was used to determine the choice of variables
included in model (C).
Sensitivity analyses
Previous studies comparing survival rates between
England or the UK to other countries suggested that
later diagnosis could be a factor contributing to poorer
outcomes: thus, opting to investigate or refer later in the
process of clinical presentation would contribute to the
delay in diagnosis in poorer performing jurisdictions.1 19
Both 1-year and conditional 5-year survival on surviving
at least 1 year (conditional 5-year survival) could reﬂect
a longer diagnostic interval due to delays, including in
primary care, but neither are a perfect measure of
this.21 We chose 1-year survival as the primary outcome
measure as we anticipated that it more directly reﬂects
activity in primary care. We then undertook sensitivity
analysis using conditional 5-year survival to check that
our ﬁndings were also conﬁrmed using this outcome.
Denmark has substantially changed its primary care
referral procedures since the latest reported comparative
survival ﬁgures.22 23 This change in procedures was
apparent in the results, with Denmark appearing as an
outlier in vignettes 3 and 4 related to the diagnosis of
colorectal cancer; analyses of these two vignettes were
repeated excluding Denmark.
Australia oversampled rural PCPs to ensure the views of
this minority were adequately represented. A post hoc sen-
sitivity analysis was undertaken to address this: we formed a
data set with a sample of rural PCPs so that this was repre-
sentative of the rural/urban split in Australia and com-
pared these with the results of the whole data set.
Governance
At all stages, the methodology, sampling and analysis
were discussed with four separate working groups: the
module lead of each jurisdiction, the Programme Board
overseeing the whole ICBP programme, an academic
steering group comprising the module chair and three
academic PCPs with an interest in cancer (PWR, GR,
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WH, PV) and an academic reference group comprising
primary care academics from within and outside ICBP
jurisdictions.
RESULTS
The online survey was completed by 2795 PCPs. Almost
all jurisdictions received at least 200 responses; only the
Northern Ireland response (the smallest total popula-
tion) was below this target but with a GP population of
1165 clinicians their crude response rate amounted to
11.2%. Crude response rates (most jurisdictions stopped
the survey when the sample size was reached) varied
between jurisdictions, from 5.5% in England and British
Columbia to 45.6% in Manitoba (see online supplemen-
tary appendix table 1).
Characteristics of respondents are summarised in see
online supplementary table S4. There were signiﬁcantly
more women PCPs in the samples from Victoria, Ontario
and British Columbia and fewer from Norway, when com-
pared with their national data. The samples from England,
Wales, Northern Ireland, New South Wales, Victoria,
Sweden, Norway and Ontario had fewer doctors who had
qualiﬁed outside the country, and Manitoba had more
(for Canadian provinces and Australian states this meant
training outside Canada and Australia, respectively).
Respondents from England and Norway were older,
whereas respondents from New South Wales and all
Canadian provinces were younger, compared with national
data. Acknowledging that conﬁdence intervals would be
wider than anticipated, Northern Ireland was included for
completeness.
Vignette results
In 4 of the 5 vignettes, there was a statistically signiﬁcant
correlation (p<0.05) between opting to investigate for
cancer in a jurisdiction at phase 1 and the cancer sur-
vival in that jurisdiction (ﬁgure 1). Only phase 1 results
are presented; nearly all PCPs had taken action to refer
or investigate for a potential diagnosis of cancer by the
end of phase 2.
Vignette 1 (lung cancer) was the only vignette that did
not show any statistically signiﬁcant correlations. In this
vignette, the estimated PPV for lung cancer for the
symptoms presented at phase 1 was 0.9% (although this
was not explicitly presented in the vignette) and yet the
range of respondents opting to investigate at this phase
between jurisdictions was 40–80% (table 1). The esti-
mated PPV for lung cancer in phase 1 of vignette 2 was
higher at 3.6% and yet the range of respondents opting
to investigate at this phase was 4–52%.
The lung and ovarian cancer vignettes were usually
completed by the use of a test (chest X-ray for lung
cancer, ultrasound for ovarian cancer) rather than by
specialist referral. In contrast, more than half of the
colorectal vignettes were completed by referral.
Consistent with the correlation results, statistically signiﬁ-
cant associations were found using weighted regression
between the 1-year survival and readiness to investigate at
phase 1 for vignettes 2, 3, 4 (after Denmark was excluded)
and 5. For the sensitivity analysis based on the conditional
5-year survival, this association was found at phase 1
for vignettes 2, 3 and 4 (after Denmark was excluded;
table 1).
Logistic regression analysis
No factors (PCP characteristics, access to tests or length
of time from ordering test to receiving results) showed a
consistent association with the readiness to investigate.
The only two PCP characteristics associated with the
outcome were that doctors who trained outside their jur-
isdiction were more likely to refer or investigate cases
earlier in vignettes 3 and 4 (both colorectal) and older
doctors were more likely to refer or investigate cases
earlier in vignette 4. The former association was investi-
gated further using data from Manitoba (the only juris-
diction to have more doctors trained outside of the
jurisdiction); within this data set there was no association
found between place of training and readiness to investi-
gate. The latter association was no longer statistically sig-
niﬁcant when excluding Denmark as part of the
sensitivity analysis; while training outside was still signiﬁ-
cant (data not shown).
Similarly, adjusting for rural/urban split among
Australian PCPs did not signiﬁcantly affect the results.
Direct questions: access to diagnostics and secondary
care advice
Similarities and differences in primary care system
factors are reported between jurisdictions. Reported
direct access to blood tests for cancer diagnosis, plain
X-rays and ultrasound was greater than 70% across all
jurisdictions (table 2). Access to other tests was variable.
Direct access to endoscopy was less common in Canada.
The UK and Denmark had comparatively low levels of
direct access to CT and MRI scanning.
With the exception of plain X-rays, the total wait from
request to receipt of report for imaging or endoscopy
was reported to be over 4 weeks in most jurisdictions
and over 12 weeks in some. Total wait between a referral
for a suspected cancer and a patient’s ﬁrst specialist
appointment was between 2 and 3 weeks for all jurisdic-
tions (table 3). Most PCPs reported they could expedite
access to tests if cancer was suspected. With the excep-
tion of the UK, most PCPs reported ready access to sec-
ondary care advice about investigation or referral of
suspected cancer (table 4).
While there was variation across jurisdictions in terms of
access to diagnostics and secondary care advice, none of
these factors were associated with PCP readiness to act.
DISCUSSION
Principal findings
Using an online survey in 11 jurisdictions, we have
demonstrated a correlation that suggests a relationship
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between the readiness of PCPs to investigate or refer for
suspected cancer and cancer survival in each jurisdic-
tion. This is the ﬁrst time that readiness to investigate
cancer—either directly or by referral to secondary care
—has been shown to correlate with cancer survival.
Evidence suggests that variations between healthcare
systems have an impact on health outcomes.24 There is
signiﬁcant variation between jurisdictions in PCP’s
access to diagnostic tests. Whether greater access to tests
improves outcomes depends on the sensitivity of the test
and how the waiting time for test results compares with
the waiting time if a referral is made. PCPs may not be
aware of the fastest way to diagnose cancer: referral or
primary care investigation. Our data indicate signiﬁ-
cantly long waits in some jurisdictions for the results of
tests undertaken in primary care. However, access to
tests was not associated with readiness to investigate or
refer. Further research is required in this complex area.
Strengths and weaknesses
This was a novel, large, logistically complex survey using
a validated tool in 11 jurisdictions with primary care-
based health systems. Once respondents engaged in the
online survey, the proportion who went on to complete
it was high. The vignettes had face validity; they directly
reﬂected clinical practice and were universally
Figure 1 Scatterplots of vignettes and multiple regression analysis (PCP, primary care physicians).
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applicable.17 Moreover, since the study was completed,
the vignettes have been adopted as part of a GP educa-
tion programme in the UK, in light of their applicability
to primary care. There is evidence that using vignettes
in a survey correlates well to clinical practice.25 Vignettes
have also been used recently in a similar context.26
While surveys using hypothetical vignettes are not ideal,
we chose vignette-based surveys as a cost-effective way to
maintain consistency across all jurisdictions.
The readiness of PCPs to act consists of personal attri-
butes (eg, knowledge and attitudes about cancer as well
as perceptions about the role of PCPs) and system fea-
tures (eg, guidelines, availability of tests/referral and
waiting time for results). A multiple regression analysis
Figure 1 Continued
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did not ﬁnd a signiﬁcant association with any of these
factors.
This study used an ecological outcome, which makes
the risk of an ecological fallacy important. We do not
know whether the correlation with readiness and survival
is causal or simply an indicator of other factors.
Therefore, this study raises the potential of an inter-
action between the PCPs’ readiness and the system in
which they act. These results add to the science pointing
towards this important implication.
The poor response rates in some jurisdictions and the
lack of representativeness of the respondents in several
jurisdictions (based on demographic data) are weak-
nesses. It is difﬁcult to assess whether and by how much
these two factors would affect the interpretation of the
results. Two jurisdictions achieved a response rate of
over 25%; in other jurisdictions, response rates ranged
from 5.5% to 18.7%. A signiﬁcant obstacle to achieving
better response rates in some jurisdictions was limited
availability of comprehensive and up-to-date email
addresses for PCPs. The response rates achieved are
broadly in line with lower response rates for online
surveys generally.27 Furthermore, response rates in phys-
ician surveys have been declining in recent years.28
Those responding were not wholly representative of
their local PCP population, but the differences in
gender and country of qualiﬁcation were bidirectional.
Evidence from Australia suggests that while respondents
had more positive views about cancer compared to non-
responders, the magnitude of this difference is the same
irrespective of incentives (conditional or otherwise).29
In addition, respondents were aware the survey was part
of a study linked to cancer for ethical reasons; responses
might have been different in a blinded study. Taken
together, these biases tend to underestimate the possible
variation, and our results are thus minimum estimates of
the correlation between readiness to investigate and sur-
vival. In jurisdictions where respondents were less repre-
sentative of the local PCP population, respondents were
in general more likely to be women, to have qualiﬁed in
that country and to be younger. Although training
outside the country was associated with opting to act
earlier in the colorectal vignettes, sensitivity analysis
using Manitoba data suggested this is unlikely to have
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Table 2 Direct access* to investigations (%)
Australia Canada
Denmark Norway Sweden
UK
NSW Victoria British Columbia Manitoba Ontario England Northern Ireland Wales
Cancer diagnosis blood tests†
Blood tests
95% CI
98.0
95.2 to 99.3
99.5
96.6 to 100
81.7
75.9 to 86.3
69.3
62.8 to 75.1
80.7
77.2 to 83.7
89.8
85.3 to 93.1
70.9
64.5 to 76.6
75.8
69.1 to 81.4
94.0
90.1 to 96.5
89.0
81.2 to 93.9
75.7
69.3 to 81.1
Endoscopy
Upper GI endoscopy
95% CI
26.0
20.8 to 31.9
66.1
58.9 to 72.8
7.4
4.5 to 11.8
13.7
9.6 to 18.9
19.5
16.4 to 22.9
56.5
50.1 to 62.6
18.0
13.2 to 23.5
46.2
38.9 to 53.2
68.1
61.9 to 73.8
68.5
59.1 to 77.2
66.1
59.3 to 72.2
Flexi sigmoidoscopy
95% CI
17.7
13.3 to 23.1
34.9
28.2 to 42.2
13.1
9.2 to 18.3
13.2
9.2 to 18.4
17.7
14.7 to 21.0
54.9
48.6 to 61.1
16.2
11.7 to 21.6
34.2
27.8 to 41.5
40.6
34.6 to 47.0
14.8
8.9 to 23.0
32.3
26.1 to 38.8
Colonoscopy
95% CI
26.4
21.1 to 32.3
61.9
54.5 to 68.8
7.9
4.9 to 12.3
13.2
9.2 to 18.4
22.4
19.1 to 26.0
52.5
46.2 to 58.8
17.1
12.5 to 22.6
45.2
37.9 to 52.2
33.1
27.4 to 39.3
19.8
13.3 to 29.2
22.0
16.8 to 28.2
Imaging
X-ray whole body‡
95% CI
99.2
96.9 to 99.9
100.0
97.5 to 100
96.1
92.4 to 98.1
92.5
88.1 to 95.5
98.0
96.4 to 98.9
92.2
88.0 to 95.0
74.3
68.1 to 79.8
86.4
80.6 to 90.7
82.5
77.1 to 86.9
89.9
82.3 to 94.6
87.6
82.3 to 91.5
CT whole body
95% CI
99.6
97.5 to 100
100.0
97.5 to 100
92.6
88.2 to 95.5
86.4
81.1 to 90.4
95.1
93 to 96.7
22.0
17.1 to 27.7
73.5
67.2 to 79.0
84.3
78.4 to 89.0
21.5
16.7 to 27.2
27.5
19.6 to 37.0
46.3
39.6 to 53.2
MRI whole body
95% CI
44.9
38.7 to 51.2
54.0
46.6 to 61.2
62.0
55.4 to 68.3
74.6
68.3 to 80.0
91.6
89 to 93.6
16.9
12.6 to 22.2
70.4
64.0 to 76.2
68.2
61.1 to 74.5
19.9
15.3 to 25.5
11.0
6.1 to 18.8
31.2
25.2 to 37.9
Ultrasound whole body
95% CI
98.0
95.2 to 99.3
98.9
95.8 to 99.8
93.0
88.7 to 95.8
84.2
78.7 to 88.6
95.4
93.4 to 96.9
78.2
72.4 to 82.9
70.9
64.5 to 76.6
82.3
76.1 to 87.2
78.1
72.4 to 82.9
79.8
70.8 to 86.7
71.1
64.5 to 76.9
Exact 95% CI calculated for these figures.
*Direct access: primary care physicians can order the test without specific referral to secondary care.
†Survey did not define which specific tests.
‡Access to all individual body parts.
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Table 3 Average wait times for tests and results (weeks)
Australia Canada
Denmark Norway Sweden
UK
NSW Victoria
British
Columbia Manitoba Ontario England
Northern
Ireland Wales
X-ray
Test 0.56 0.57 0.56 0.55 0.54 0.95 1.37 1.43 0.79 0.91 0.82
Result 0.50 0.51 0.71 0.68 0.57 0.79 0.69 0.67 1.03 1.36 1.28
Total wait 1.06 1.08 1.27 1.23 1.11 1.74 2.06 2.10 1.82 2.27 2.10
95% CI 1.00 to 1.12 1.03 to 1.13 1.17 to 1.37 1.15 to 1.32 1.08 to 1.13 1.62 to 1.86 1.91 to 2.21 1.88 to 2.33 1.68 to 1.95 2.01 to 2.52 1.94 to 2.25
CT
Test 0.81 0.82 4.29 4.13 3.01 2.65 3.30 4.07 3.50 5.55 5.38
Result 0.52 0.52 1.02 0.96 0.78 0.98 0.85 1.02 1.39 1.77 1.44
Total wait 1.33 1.34 5.31 5.09 3.79 3.63 4.15 5.09 4.89 7.32 6.82
95% CI 1.24 to 1.42 1.24 to 1.44 4.87 to 5.75 4.69 to 5.49 3.59 to 3.68 3.33 to 3.93 3.88 to 4.43 4.60 to 5.57 4.60 to 5.18 6.57 to 8.07 6.35 to 7.29
MRI
Test 2.39 2.76 12.36 9.10 6.05 5.06 6.13 6.16 4.73 9.04 8.37
Result 0.60 0.56 1.39 1.36 0.88 1.12 1.05 1.24 1.52 2.55 1.56
Total wait 2.99 3.32 13.75 10.46 6.93 6.18 7.18 7.40 6.25 11.60 9.93
95% CI 2.64 to 3.34 2.84 to 3.80 13.12 to 14.38 9.82 to 11.09 6.61 to 7.25 5.66 to 6.69 6.72 to 7.63 6.73 to 8.06 5.90 to 6.60 10.63 to 12.57 8.32 to 30.55
Ultrasound
Test 1.11 1.26 4.30 5.88 1.80 2.71 3.99 3.76 3.73 6.38 6.08
Result 0.52 0.53 0.88 1.04 0.65 0.84 0.78 0.93 1.19 1.62 1.31
Total wait 1.63 1.79 5.18 6.92 2.46 3.55 4.77 4.69 4.93 8.00 7.39
95% CI 1.50 to 1.76 1.56 to 2.02 4.71 to 5.66 6.36 to 7.48 2.32 to 2.59 3.23 to 3.88 4.39 to 5.14 4.25 to 5.13 4.64 to 5.21 7.35 to 8.66 6.90 to 7.88
Upper GI endoscopy
Test 5.56 5.11 9.05 9.35 6.01 2.45 5.95 4.71 3.99 8.37 8.17
Result 1.38 0.83 1.49 1.82 1.36 0.77 0.95 1.46 1.35 1.58 1.67
Total wait 6.94 5.94 10.54 11.17 7.37 3.22 6.90 6.17 5.34 9.95 9.84
95% CI 6.35 to 7.53 5.24 to 6.64 9.85 to 11.72 10.49 to 11.84 1.03 to 7.72 2.97 to 3.47 6.45 to 7.35 5.63 to 6.72 5.02 to 5.66 9.16 to 10.74 9.18 to 10.50
Flexi sigmoidoscopy
Test 5.26 5.06 9.19 9.01 5.79 2.39 6.28 5.55 4.15 8.21 8.20
Result 1.38 0.87 1.55 1.91 1.34 0.76 0.94 1.54 1.46 2.04 1.66
Total wait 6.64 5.93 10.74 10.91 7.14 3.15 7.22 7.09 5.61 10.25 9.86
95% CI 6.06 to 7.22 5.21 to 6.65 10.03 to 11.44 10.20 to 11.63 6.75 to 7.48 2.89 to 3.41 6.76 to 7.65 6.53 to 7.65 5.26 to 5.95 9.35 to 11.15 9.21 to 10.50
Colonoscopy
Test 5.78 5.36 10.48 10.16 6.70 2.51 6.69 6.25 4.15 8.69 9.06
Result 1.38 0.84 9.61 1.91 1.37 0.78 0.98 1.54 1.56 2.00 1.70
Total wait 7.16 6.20 20.09 12.07 8.08 3.29 7.67 7.79 5.71 10.69 10.76
95% CI 6.54 to 7.78 5.49 to 6.91 19.13 to 21.06 11.38 to 12.75 7.72 to 8.43 3.01 to 3.58 7.20 to 8.13 7.16 to 8.41 5.33 to 6.08 9.80 to 11.58 10.08 to 11.44
Average wait time between a referral and first specialist appointment (days)
95% CI Not available Not available 15.44 19.21 15.05 4.90 13.70 14.50 10.09 13.53 18.05
Not available Not available 14.10 to 16.78 17.56 to 20.87 14.25 to 15.85 4.78 to 5.32 12.72 to 14.68 13.32 to 15.68 9.91 to 10.28 12.62 to 14.44 16.75 to 19.35
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substantially affected overall results. A systematic review
of studies of primary care referrals suggested that less
than 10% of the observed variation in referral rates
could be accounted for by practice and GP character-
istics.30 It is therefore unlikely that the minor unrepre-
sentativeness of some samples has materially altered the
ﬁndings. Other hidden confounders may have inﬂu-
enced the results, but they are unlikely to have been
major.
Earlier diagnosis could lead to perceived better out-
comes through two mechanisms: earlier stage at diagno-
sis or lead time bias. Our correlations were signiﬁcant
for both 1-year and conditional 5-year survival, suggest-
ing that lead time bias is less of an issue.
The vignettes all described hypothetical patients with
symptoms that have been shown to be signiﬁcantly asso-
ciated with the given cancer.
The survey was conducted in 2012/2013 and there-
fore reﬂects clinical practice at that time. The latest
comparative survival data for the three cancers in par-
ticipating jurisdictions is from 2007. The jurisdictions
had no major changes to cancer diagnostic pathways
during that time, with the exception of Denmark,
which in 2009, introduced signiﬁcant reforms to
improve diagnostic access for PCPs. Consequently,
Denmark was often an outlier in the analyses: sensitivity
analyses including and excluding Denmark strength-
ened our ﬁndings.
Comparison with other research
An analysis of the health systems in the ICBP jurisdictions
showed few signiﬁcant differences.15 Poorer outcomes
have been correlated with the strength of the ‘gatekeep-
ing’ role of PCPs in different health systems13: our ﬁndings
broadly support this. Denmark has deliberately reorga-
nised cancer diagnostic services to reduce the gatekeeping
role by enabling PCPs to undertake timely investigation of
patients with alarming as well as vague symptoms.23 Our
results suggest that Danish PCPs now behave more simi-
larly to PCPs in jurisdictions with better cancer outcomes.
Gatekeeping may encourage PCPs to overuse other diag-
nostic strategies, such as the ‘test of time’, which could
contribute to longer diagnostic intervals.31 Other possible
reasons to account for our results include PCPs’ knowl-
edge and PCPs’ relationships with specialists.
Implications
In this study, PCPs opted to investigate at low levels of
risk, possibly reﬂecting bias, because this was a survey
relating to cancer. However, recent work suggests that
patients prefer to be investigated when cancer is a possi-
bility even at low-risk levels.25 If risk thresholds at which
symptoms are investigated were to be lowered, health
economic considerations would need to be taken into
account. The use of risk prediction tools32 33 may aid
PCPs in this respect. Our ﬁndings also suggested that
PCPs were not necessarily aware of the PPVs of groups
of symptoms. Across all jurisdictions, the speed of
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referral was inversely related to the PPV for lung cancer
in the two lung vignettes. However, these counter-
intuitive responses are consistent with referral guidelines
in some of the jurisdictions. Variation in readiness to
investigate or refer to secondary care by PCPs for
patients with a differential diagnosis of cancer might
explain some of the variation in cancer survival between
ICBP jurisdictions. It is unlikely that a single solution to
this variation will work across all jurisdictions. However,
solutions are likely to include initiatives that empower
PCPs towards earlier investigation of cancer and to
reduce the barriers that inhibit specialist referral. Such
changes are likely to require changes in local policy
leading to increased access to investigations and diagnos-
tics, more efﬁcient referral pathways and the redrafting
of local referral guidelines, to facilitate referral at risk
levels below those currently mandated.
Future research
The study supports the ecological ﬁndings that there is a
correlation between the healthcare system and the way
PCPs perform clinical diagnosis. Therefore, it seems
appropriate to perform studies to assess which factors
affect the readiness of a PCP to investigate or refer, for
example, changed access to investigations, the nature and
recommendations of clinical guidelines, access to rapid
diagnostics and referral, and the nature of relationships
between primary and secondary care. Further studies on
using alternate outcome measures such as stage distribu-
tion, and cohort studies on survival and mortality, could
provide additional insights into these factors.
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